Immix Biopharma Inc

Research Immix Biopharma Inc (IMMX) on Bullrun: market cap USD 570.78M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerIMMX
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 570.78M
• Financial periodFY2025
• Net income-USD 29.40M
• Free cash flow-USD 24.66M

Valuation Snapshot

latest market cap is USD 570.78M.

About Immix Biopharma Inc

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.

Frequently asked questions

What is Immix Biopharma Inc's market cap?

Immix Biopharma Inc's market capitalization is USD 570.78M.

What does Immix Biopharma Inc do?

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.